ZoomRx Launches Sagan Agents to Automate Pharma Market Research with AI

BOSTON, MA – May 20, 2026 – Strategic life sciences consultancy ZoomRx today announced the launch of Sagan Agents, an AI-driven enterprise operating system designed to fundamentally reshape how pharmaceutical companies generate and use customer insights. The platform aims to transform the traditionally slow and costly process of market research into a continuous, automated intelligence loop, potentially compressing workflows that take weeks into a matter of hours or days.

ZoomRx, which serves 19 of the top 20 global biopharma companies, is leveraging its extensive industry footprint to power the new system. Sagan Agents is built upon a proprietary data foundation amassed over 15 years, comprising over 700 million benchmark datapoints and access to exclusive panels of healthcare professionals (HCPs) and patients. The launch marks a significant step in the application of specialized AI to one of the biopharma industry's most critical and resource-intensive functions.

The Agentic AI Revolution in Pharma Insights

At the heart of Sagan Agents is the concept of "agentic AI," a more advanced form of artificial intelligence designed to autonomously execute complex, multi-step tasks. Instead of simply analyzing data, these AI agents are built to manage entire workflows, from posing a business question to delivering a complete, evidence-backed presentation.

Pharma brand teams traditionally invest millions annually per brand on market research studies, yet much of the resulting knowledge becomes siloed in old reports and datasets. Sagan Agents confronts this challenge with its "Data Archive Intelligence" feature, which ingests a company's entire commercial knowledge base—including quantitative data, qualitative transcripts, claims data, and past reports. This creates a centralized, intelligent archive that AI agents can instantly query.

"Most pharma AI platforms are generic infrastructure pointed at proprietary data. They give you the engine and ask you to figure out the rest," said Ty Harkness, Head of Sagan Agents at ZoomRx, in the company's announcement. "We built Sagan Agents on a different premise: the value is in the workflow, not the infrastructure. We've encoded 15 years of pharma analytical expertise as agent skills."

This workflow-centric approach allows for the creation of "Strategic Insights Agents" tailored to specific research needs like market segmentation, message testing, patient journey mapping, or brand health tracking. The system's "Agentic Market Research" capability can automate the entire research process, from study design and fielding to analysis and reporting. This allows teams to identify and address knowledge gaps on an ongoing basis rather than in discrete, lengthy cycles.

Building Trust in a Highly Regulated Industry

While the promise of AI-driven speed is compelling, its adoption in the biopharma sector hinges on trust, security, and regulatory compliance. Handling sensitive patient data, competitive intelligence, and information governed by frameworks like HIPAA and GDPR requires a level of security and transparency far beyond that of a typical enterprise tool. ZoomRx has built Sagan Agents with these non-negotiable requirements at its core.

The platform's architecture emphasizes enterprise-grade security through three key pillars. First, Data Sovereignty ensures logical isolation of client data through a multi-tenant architecture and contracts with LLM providers that prevent them from retaining or training on client inputs. Second, Access Governance utilizes role-based controls to restrict who can see specific data at the brand or indication level, with all activity logged in comprehensive audit trails.

Most critically, the system is designed for Output Integrity. Every insight, chart, or conclusion generated by an agent is linked directly back to the source data, documents, and studies that informed it. This creates a verifiable evidence trail, a feature essential for internal validation and potential regulatory scrutiny.

“Enterprise AI in biopharma lives or dies on trust," noted Sivakumar K, VP of Technology at ZoomRx. "What we can show is a complete evidence trail on every single output - every source, every inference, every data point that informed the answer. This is how you build trust with a brand team that puts AI-generated insights in front of their leadership.”

Redefining the Role of the Insights Professional

The introduction of powerful automation tools like Sagan Agents is poised to catalyze a significant evolution in the role of market research and insights professionals. Rather than replacing human expertise, such platforms aim to augment it by automating the most time-consuming and repetitive aspects of the job. Industry analysts have noted a broader trend where AI handles the heavy lifting of data collection, processing, and initial analysis, freeing up human experts to focus on higher-value strategic activities.

This shift allows insights professionals to move from being data wranglers to strategic partners. Their focus can transition to interpreting nuanced AI-generated findings, validating complex conclusions, identifying subtle knowledge gaps the AI may not recognize, and formulating sophisticated brand strategies. The human-AI collaboration model promises a future where professionals can test hypotheses and explore scenarios at a speed previously unimaginable, leading to more dynamic and responsive decision-making.

The platform's ability to create a "continuous intelligence loop" supports this evolution. Instead of waiting weeks for a study to conclude, teams can receive a constant flow of information, allowing them to iterate on strategy in near real-time as market conditions change. This agility is a key competitive advantage in the fast-paced pharmaceutical landscape.

A Competitive Edge in a Crowded Field

ZoomRx enters an active market where major consulting and data analytics firms like ZS Associates and IQVIA are also investing heavily in AI-powered solutions for the life sciences. However, Sagan Agents is positioned not as another analytics tool, but as a comprehensive "operating system" for insights. Its differentiation lies in its explicit focus on agentic workflows, its foundation on ZoomRx's deep, 15-year repository of pharma-specific data, and its established relationships with the world's leading biopharma companies.

By offering the platform via a per-brand annual subscription priced comparably to a single large traditional market research study, ZoomRx is making a clear value proposition: for the cost of one slow, static project, a brand team can gain access to a continuous, always-on intelligence engine. This model could significantly lower the barrier to adopting advanced AI, allowing more teams to benefit from a new standard of speed, depth, and efficiency in understanding their customers and markets.